Please enable JavaScript to continue using this application.

Compare tickers

Valuation, margins, and growth side by side.

Compare $AXSM vs $LGND | Chartloom

Compare

$AXSM vs $LGND

Axsome Therapeutics Inc · Ligand Pharmaceuticals Inc

AXSM

Axsome Therapeutics Inc

LGND

Ligand Pharmaceuticals Inc

Compare $AXSM vs $LGND

Comparing Axsome Therapeutics Inc and Ligand Pharmaceuticals Inc

AXSMAxsome Therapeutics Inc

LGNDLigand Pharmaceuticals Inc

AXSMAxsome Therapeutics Inc

Market cap

$8.04B

P/E (TTM)

—

Forward P/E (NTM)

211.90x

Forward P/S (NTM)

6.58x

Rev growth (TTM)

56.9%

YTD performance

-12.5%

52W performance

28.4%

FCF yield

-0.9%

LGNDLigand Pharmaceuticals Inc

Market cap

$6.08B

P/E (TTM)

33.61x

Forward P/E (NTM)

28.81x

Forward P/S (NTM)

17.73x

Rev growth (TTM)

54.9%

YTD performance

59.7%

52W performance

70.8%

FCF yield

2.2%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

AXSM

LGND

Detailed metrics comparison

AXSM

Axsome Therapeutics Inc

LGND

Ligand Pharmaceuticals Inc

Market Cap

AXSM$8.04B

LGND$6.08B

Enterprise Value

AXSM$7.93B

LGND$6.20B

Price

AXSM$156.32

LGND$303.53

P/E Ratio

AXSMN/A

LGND33.61x

P/S Ratio

AXSM10.36x

LGND20.94x

EV/Sales

AXSM10.21x

LGND21.35x

EV/EBITDA

AXSM0.00x

LGND42.81x

P/B Ratio

AXSM105.86x

LGND6.22x

P/FCF Ratio

AXSMN/A

LGND45.31x

EV/FCF

AXSM-110.16x

LGND46.20x

PEG Ratio

AXSMN/A

LGND1.33x

Forward P/E (NTM)

AXSM211.90x

LGND28.81x

Forward P/S (NTM)

AXSM6.58x

LGND17.73x

Revenue (TTM)

AXSM$777M

LGND$291M

Revenue Growth (YoY)

AXSM56.9%

LGND54.9%

Forward Rev Growth

AXSM59.9%

LGND31.3%

Gross Margin (TTM)

AXSM93.2%

LGND95.4%

Operating Margin (TTM)

AXSM0.0%

LGND32.6%

EBITDA Margin (TTM)

AXSM-23.0%

LGND45.8%

Net Margin (TTM)

AXSM-24.7%

LGND67.9%

FCF Margin (TTM)

AXSM-9.3%

LGND46.2%

Net Income (TTM)

AXSM$-192M

LGND$197M

FCF (TTM)

AXSM$-72M

LGND$134M

EPS (TTM)

AXSM-$3.70

LGND$9.03

ROE (TTM)

AXSM-25560.0%

LGND20.1%

ROA (TTM)

AXSM-2705.0%

LGND11.7%

ROIC (TTM)

AXSM-7042.0%

LGND12.3%

Cash

AXSM$320M

LGND$1.01B

Debt

AXSM$202M

LGND$1.13B

Net Cash/Debt

AXSM$117M

LGND$-120M

Current Ratio (TTM)

AXSM1.43x

LGND31.18x

Quick Ratio (TTM)

AXSM1.30x

LGND30.96x

Debt/Equity (TTM)

AXSM2.43x

LGND1.16x

Debt/Assets (TTM)

AXSM0.0%

LGND0.0%

Interest Coverage (TTM)

AXSMN/A

LGNDN/A

Net Debt/EBITDA (TTM)

AXSM0.00x

LGND0.00x

Beta

AXSM0.79

LGND1.23

52W Performance

AXSM28.4%

LGND70.8%

YTD Performance

AXSM-12.5%

LGND59.7%

% from 52W High

AXSM-39.9%

LGND-7.1%

% from 52W Low

AXSM31.1%

LGND72.6%

Asset Turnover (TTM)

AXSM1.10x

LGND0.17x

FCF Yield (TTM)

AXSM-0.9%

LGND2.2%

Earnings Yield (TTM)

AXSM-2.4%

LGND3.2%

Dividend Yield (TTM)

AXSMN/A

LGNDN/A

Rule of 40

AXSM47.6

LGND101.1

EV/GP/RG

AXSM0.19

LGND1.14

Ticker research

View AXSM research View LGND research

Metric	AXSM Axsome Therapeutics Inc	LGND Ligand Pharmaceuticals Inc
Market & Valuation
Market Cap	$8.04B	$6.08B
Enterprise Value	$7.93B	$6.20B
Price	$156.32	$303.53
P/E Ratio	N/A	33.61x
P/S Ratio	10.36x	20.94x
EV/Sales	10.21x	21.35x
EV/EBITDA	0.00x	42.81x
P/B Ratio	105.86x	6.22x
P/FCF Ratio	N/A	45.31x
EV/FCF	-110.16x	46.20x
PEG Ratio	N/A	1.33x
Forward P/E (NTM)	211.90x	28.81x
Forward P/S (NTM)	6.58x	17.73x
Revenue & Growth
Revenue (TTM)	$777M	$291M
Revenue Growth (YoY)	56.9%	54.9%
Forward Rev Growth	59.9%	31.3%
Profitability
Gross Margin (TTM)	93.2%	95.4%
Operating Margin (TTM)	0.0%	32.6%
EBITDA Margin (TTM)	-23.0%	45.8%
Net Margin (TTM)	-24.7%	67.9%
FCF Margin (TTM)	-9.3%	46.2%
Net Income (TTM)	$-192M	$197M
FCF (TTM)	$-72M	$134M
EPS (TTM)	-$3.70	$9.03
ROE (TTM)	-25560.0%	20.1%
ROA (TTM)	-2705.0%	11.7%
ROIC (TTM)	-7042.0%	12.3%
Financial Health
Cash	$320M	$1.01B
Debt	$202M	$1.13B
Net Cash/Debt	$117M	$-120M
Current Ratio (TTM)	1.43x	31.18x
Quick Ratio (TTM)	1.30x	30.96x
Debt/Equity (TTM)	2.43x	1.16x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.79	1.23
52W Performance	28.4%	70.8%
YTD Performance	-12.5%	59.7%
% from 52W High	-39.9%	-7.1%
% from 52W Low	31.1%	72.6%
Efficiency & Yields
Asset Turnover (TTM)	1.10x	0.17x
FCF Yield (TTM)	-0.9%	2.2%
Earnings Yield (TTM)	-2.4%	3.2%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	47.6	101.1
EV/GP/RG	0.19	1.14
Ticker research	View AXSM research	View LGND research

Valuation

P/E Ratio

LGND

33.61x

P/S Ratio

AXSM

10.36x

LGND

20.94x

EV/FCF

AXSM

-110.16x

LGND

46.20x

Growth & revenue

Revenue Growth TTM

AXSM

56.9%

LGND

54.9%

Forward Revenue Growth

AXSM

59.9%

LGND

31.3%

Profitability & performance

Gross Margin

LGND

95.4%

AXSM

93.2%

ROE

LGND

20.1%

AXSM

-25560.0%

FCF Yield %

LGND

2.2%

AXSM

-0.9%

52-Week Performance

LGND

70.8%

AXSM

28.4%

Detailed metrics comparison

AXSM

Axsome Therapeutics Inc

LGND

Ligand Pharmaceuticals Inc

Market Cap

AXSM$8.04B

LGND$6.08B

Enterprise Value

AXSM$7.93B

LGND$6.20B

Price

AXSM$156.32

LGND$303.53

P/E Ratio

AXSMN/A

LGND33.61x

P/S Ratio

AXSM10.36x

LGND20.94x

EV/Sales

AXSM10.21x

LGND21.35x

EV/EBITDA

AXSM0.00x

LGND42.81x

P/B Ratio

AXSM105.86x

LGND6.22x

P/FCF Ratio

AXSMN/A

LGND45.31x

EV/FCF

AXSM-110.16x

LGND46.20x

PEG Ratio

AXSMN/A

LGND1.33x

Forward P/E (NTM)

AXSM211.90x

LGND28.81x

Forward P/S (NTM)

AXSM6.58x

LGND17.73x

Revenue (TTM)

AXSM$777M

LGND$291M

Revenue Growth (YoY)

AXSM56.9%

LGND54.9%

Forward Rev Growth

AXSM59.9%

LGND31.3%

Gross Margin (TTM)

AXSM93.2%

LGND95.4%

Operating Margin (TTM)

AXSM0.0%

LGND32.6%

EBITDA Margin (TTM)

AXSM-23.0%

LGND45.8%

Net Margin (TTM)

AXSM-24.7%

LGND67.9%

FCF Margin (TTM)

AXSM-9.3%

LGND46.2%

Net Income (TTM)

AXSM$-192M

LGND$197M

FCF (TTM)

AXSM$-72M

LGND$134M

EPS (TTM)

AXSM-$3.70

LGND$9.03

ROE (TTM)

AXSM-25560.0%

LGND20.1%

ROA (TTM)

AXSM-2705.0%

LGND11.7%

ROIC (TTM)

AXSM-7042.0%

LGND12.3%

Cash

AXSM$320M

LGND$1.01B

Debt

AXSM$202M

LGND$1.13B

Net Cash/Debt

AXSM$117M

LGND$-120M

Current Ratio (TTM)

AXSM1.43x

LGND31.18x

Quick Ratio (TTM)

AXSM1.30x

LGND30.96x

Debt/Equity (TTM)

AXSM2.43x

LGND1.16x

Debt/Assets (TTM)

AXSM0.0%

LGND0.0%

Interest Coverage (TTM)

AXSMN/A

LGNDN/A

Net Debt/EBITDA (TTM)

AXSM0.00x

LGND0.00x

Beta

AXSM0.79

LGND1.23

52W Performance

AXSM28.4%

LGND70.8%

YTD Performance

AXSM-12.5%

LGND59.7%

% from 52W High

AXSM-39.9%

LGND-7.1%

% from 52W Low

AXSM31.1%

LGND72.6%

Asset Turnover (TTM)

AXSM1.10x

LGND0.17x

FCF Yield (TTM)

AXSM-0.9%

LGND2.2%

Earnings Yield (TTM)

AXSM-2.4%

LGND3.2%

Dividend Yield (TTM)

AXSMN/A

LGNDN/A

Rule of 40

AXSM47.6

LGND101.1

EV/GP/RG

AXSM0.19

LGND1.14

Ticker research

View AXSM research View LGND research

Metric	AXSM Axsome Therapeutics Inc	LGND Ligand Pharmaceuticals Inc
Market & Valuation
Market Cap	$8.04B	$6.08B
Enterprise Value	$7.93B	$6.20B
Price	$156.32	$303.53
P/E Ratio	N/A	33.61x
P/S Ratio	10.36x	20.94x
EV/Sales	10.21x	21.35x
EV/EBITDA	0.00x	42.81x
P/B Ratio	105.86x	6.22x
P/FCF Ratio	N/A	45.31x
EV/FCF	-110.16x	46.20x
PEG Ratio	N/A	1.33x
Forward P/E (NTM)	211.90x	28.81x
Forward P/S (NTM)	6.58x	17.73x
Revenue & Growth
Revenue (TTM)	$777M	$291M
Revenue Growth (YoY)	56.9%	54.9%
Forward Rev Growth	59.9%	31.3%
Profitability
Gross Margin (TTM)	93.2%	95.4%
Operating Margin (TTM)	0.0%	32.6%
EBITDA Margin (TTM)	-23.0%	45.8%
Net Margin (TTM)	-24.7%	67.9%
FCF Margin (TTM)	-9.3%	46.2%
Net Income (TTM)	$-192M	$197M
FCF (TTM)	$-72M	$134M
EPS (TTM)	-$3.70	$9.03
ROE (TTM)	-25560.0%	20.1%
ROA (TTM)	-2705.0%	11.7%
ROIC (TTM)	-7042.0%	12.3%
Financial Health
Cash	$320M	$1.01B
Debt	$202M	$1.13B
Net Cash/Debt	$117M	$-120M
Current Ratio (TTM)	1.43x	31.18x
Quick Ratio (TTM)	1.30x	30.96x
Debt/Equity (TTM)	2.43x	1.16x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.79	1.23
52W Performance	28.4%	70.8%
YTD Performance	-12.5%	59.7%
% from 52W High	-39.9%	-7.1%
% from 52W Low	31.1%	72.6%
Efficiency & Yields
Asset Turnover (TTM)	1.10x	0.17x
FCF Yield (TTM)	-0.9%	2.2%
Earnings Yield (TTM)	-2.4%	3.2%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	47.6	101.1
EV/GP/RG	0.19	1.14
Ticker research	View AXSM research	View LGND research